- Molecular NameTazobactam
- SynonymNA
- Weight300.295
- Drugbank_IDDB01606
- ACS_NO89786-04-9
- Show 3D model
- LogP (experiment)-2.227
- LogP (predicted, AB/LogP v2.0)-1.82
- pka2.1
- LogD (pH=7, predicted)-5.8
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)0.52
- LogSw (predicted, AB/LogsW2.0)320.88
- Sw (mg/ml) (predicted, ACD/Labs)3.34
- No.of HBond Donors1
- No.of HBond Acceptors9
- No.of Rotatable Bonds3
- TPSA130.84
- StatusFDA approved
- Administrationintravenous bolus
- PharmacologyA compound which inhibits the action of bacterial beta-lactamases.
- Absorption_valueN/A
- Absorption (description)N/A
- Caco_2N/A
- BioavailabilityN/A
- Protein binding30.0
- Volume of distribution (VD)0.2 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmTazobactam is metabolized to a single metabolite that lacks pharmacological and antibacterial activities. Both piperacillin and tazobactam are eliminated via the kidney by glomerular filtration and tubular secretion. Tazobactam and its metabolite are eliminated primarily by renal excretion with 80% of the administered dose excreted as unchanged drug and the remainder as the single metabolite. Piperacillin, tazobactam and desethyl piperacillin are also secreted into the bile.
- Half life0.7~1.2 h
- ExcretionN/A
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityThe most serious adverse events involved the skin (1.3%), including rash and pruritus; the gastrointestinal system (0.9%), including diarrhea, nausea, and vomiting; and allergic reactions (0.5%).
- LD50 (rat)N/A
- LD50 (mouse)N/A